**S4 Table.** Percent of scenarios changing conclusions in sensitivity analyses: Varying post-chemotherapy mortality penalty\*

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Stage I** | **None** | **CAD** | **CHF** | **COPD** | **CAD/CHF** | **CHF/COPD** | **CAD/COPD** |
| Male 80-84 years | 27% | 0% | 0% | 27% | 0% | 0% | 0% |
| Male 75-79 years | 45% | 27% | 9% | 45% | 0% | 9% | 27% |
| Male 70-74 years | 36% | 45% | 18% | 18% | 0% | 18% | 45% |
| Male 66-69 years | 18% | 55% | 27% | 9% | 9% | 27% | 45% |
| Female 80-84 years | 27% | 9% | 0% | 36% | 0% | 0% | 27% |
| Female 75-79 years | 36% | 36% | 18% | 27% | 0% | 18% | 45% |
| Female 70-74 years | 18% | 54% | 27% | 9% | 9% | 27% | 45% |
| Female 66-69 years | 9% | 45% | 36% | 0% | 9% | 45% | 27% |
|  |  |  |  |  |  |  |  |
| **Stage IIA** | **None** | **CAD** | **CHF** | **COPD** | **CAD/CHF** | **CHF/COPD** | **CAD/COPD** |
| Male 80-84 years | 36% | 9% | 0% | 27% | 0% | 0% | 9% |
| Male 75-79 years | 36% | 36% | 18% | 36% | 0% | 9% | 36% |
| Male 70-74 years | 18% | 45% | 27% | 9% | 0% | 27% | 45% |
| Male 66-69 years | 0% | 36% | 36% | 0% | 9% | 36% | 36% |
| Female 80-84 years | 36% | 18% | 0% | 45% | 0% | 0% | 18% |
| Female 75-79 years | 27% | 45% | 18% | 18% | 0% | 27% | 45% |
| Female 70-74 years | 9% | 36% | 36% | 0% | 9% | 36% | 36% |
| Female 66-69 years | 0% | 27% | 45% | 0% | 18% | 45% | 18% |
|  |  |  |  |  |  |  |  |
| **Stage IIB** | **None** | **CAD** | **CHF** | **COPD** | **CAD/CHF** | **CHF/COPD** | **CAD/COPD** |
| Male 80-84 years | 36% | 27% | 9% | 55% | 0% | 0% | 18% |
| Male 75-79 years | 0% | 36% | 36% | 0% | 9% | 27% | 45% |
| Male 70-74 years | 0% | 9% | 45% | 0% | 27% | 45% | 18% |
| Male 66-69 years | 0% | 0% | 27% | 0% | 36% | 27% | 0% |
| Female 80-84 years | 27% | 45% | 18% | 27% | 0% | 18% | 45% |
| Female 75-79 years | 0% | 18% | 45% | 0% | 27% | 45% | 18% |
| Female 70-74 years | 0% | 0% | 27% | 0% | 36% | 27% | 0% |
| Female 66-69 years | 0% | 0% | 9% | 0% | 55% | 9% | 0% |
|  |  |  |  |  |  |  |  |
| **Stage IIIA** | **None** | **CAD** | **CHF** | **COPD** | **CAD/CHF** | **CHF/COPD** | **CAD/COPD** |
| Male 80-84 years | 9% | 55% | 27% | 36% | 0% | 0% | 64% |
| Male 75-79 years | 0% | 0% | 36% | 0% | 27% | 36% | 0% |
| Male 70-74 years | 0% | 0% | 9% | 0% | 45% | 36% | 0% |
| Male 66-69 years | 0% | 0% | 0% | 0% | 27% | 0% | 0% |
| Female 80-84 years | 0% | 18% | 45% | 0% | 18% | 27% | 36% |
| Female 75-79 years | 0% | 0% | 9% | 0% | 55% | 27% | 0% |
| Female 70-74 years | 0% | 0% | 0% | 0% | 27% | 0% | 0% |
| Female 66-69 years | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
|  |  |  |  |  |  |  |
| Base-case conclusion | (no color) | Observation |  | Adjuvant chemotherapy |

\*One-way sensitivity analyses show results of simulations varying parameter for impact of adjuvant chemotherapy on post-chemotherapy mortality. Result is the proportion of simulations where the base-case prediction is maintained when varying the hazard ratio for adjuvant chemotherapy across its 95% confidence range.